Document Classification

Section Type: RESULTS

Text: However, post-hoc analysis of the subgroup of patients not using chronic inhaled tobramycin showed a 5. 7 % difference (95 % CI 1. 5-10. 1) in relative change from baseline in percent-predicted FEV1 between the ataluren and placebo groups at week 48 (-0. 7 % [-4. 0 to 2. 1] vs -6. 4 % [-9. 8 to -3. 7] ; nominal p = 0. 0082), and fewer pulmonary exacerbations in the ataluern group (1. 42 events [0. 9-1. 9] vs 2. 18 events [1. 6-2. 7] ; rate ratio 0. 60 [0. 42-0. 86] ; nominal p = 0. 0061).